Clinical trials: Hypothalamic Diseases
Growth Hormone Deficiency
Efficacy and Safety of a High Dosage Compared to the Label Dosage of Somatropin in Early Pubertal Stage Children With Growth Hormone Deficiency
Multi-center, randomized, controlled, open-label, phase III study comparing the effects of two different dosages of somatropin treatment (in-label or doubled) after 12 and 24 months of treatment, on height velocity in early…
- Trial name
- NCT00191165
- Testing
- Somatropin
- Where
- 10 sites in Italy
- Volunteers
- 27 people
- Sponsor
- Eli Lilly and Company
Acromegaly, Pituitary Gigantism
Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism
To evaluate efficacy, safety, pharmacokinetics and pharmacodynamics of pasireotide LAR in Japanese patients with active acromegaly or pituitary gigantism.
- Trial name
- NCT01673646
- Testing
- Pasireotide LAR
- Where
- 27 sites in Japan
- Volunteers
- 33 people
- Sponsor
- Novartis Pharmaceuticals
Pituitary Adenoma, Pituitary Diseases
Peri-Operative Steroid Management in Patients
During transsphenoidal resection of pituitary tumors and cysts, surgery is performed by a neurosurgeon and ear nose and throat surgeon.
- Trial name
- Steroid (NCT02084134)
- Testing
- hydrocortisone, dexamethasone
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Washington University School of Medicine
Estrogen Deficiency, Cardiovascular Disease (CVD)
Atherosclerosis, Immune Mediated Inflammation and Hypoestrogenemia in Young Women
The purpose of this study is to determine whether young women with functional hypothalamic amenorrhea (premenopausal HypoE) is associated with risk factors for pre-clinical cardiovascular disease (CVD).
- Conditions
- Estrogen Deficiency, Cardiovascular Disease (CVD), Functional Hypothalamic Amenorrhea, Endothelial Dysfunction
- Trial name
- NCT03018366
- Testing
- 17beta Estradiol, Progesterone
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Cedars-Sinai Medical Center
HIV Lipodystrophy Syndrome, Growth Hormone Deficiency
Body Composition and Adipose Tissue in HIV
In this study, the investigators will examine the effect of therapy with the Growth Hormone Releasing Hormone (GHRH) analog tesamorelin on body composition in patients with HIV lipodystrophy and central adiposity.
- Conditions
- HIV Lipodystrophy Syndrome, Growth Hormone Deficiency, Body Composition
- Trial name
- NCT03226821
- Testing
- Tesamorelin
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Columbia University
Craniopharyngioma, Hypothalamic Obesity
Intranasal Oxytocin in Hypothalamic Obesity
This research study will test if oxytocin, delivered by nasal spray, will promote weight loss in children, adolescents, and adults with Hypothalamic Obesity as compared to a placebo. The study is divided into two parts.
- Trial name
- NCT02849743
- Testing
- Syntocinon
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Shana McCormack, MD
Pituitary Tumor, ACTH-producing Pituitary Tumour
Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors
This is a phase II, open-label, 12-month pilot study in 10 patients with silent corticotroph pituitary tumors testing the hypotheses that Pasireotide long-acting release (LAR) treatment of patients with silent corticotroph…
- Trial name
- PASSILCORT (NCT02749227)
- Testing
- Pasireotide LAR
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Columbia University
Cushing's Disease
An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.
This study provided access to pasireotide sc in patients with Cushing's disease.and provided additional information for safety and efficacy of pasireotide s.c.
- Trial name
- SEASCAPE (NCT01582061)
- Testing
- Pasireotide sub-cutaneous
- Where
- 65 sites in United States, Brazil and 9 more
- Volunteers
- 104 people
- Sponsor
- Novartis Pharmaceuticals
Growth Hormone Deficiency
Differential Effects of rhGH vs. rhIGF-1 on Cardiovascular Risk Factors
The purpose of this study is to see if giving growth hormone or insulin-like growth factor-1 (IGF-1) to subjects with growth hormone deficiency effects cardiovascular risk factors differently.
- Trial name
- NCT00684957
- Testing
- Recombinant Human Growth Hormone, Recombinant Human IGF-1
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Columbia University
Acromegaly
Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients
This study will assess the efficacy of 8 months treatment of Sandostatin® LAR® High Dose monotherapy or Sandostatin® LAR® High Dose in combination either with growth hormone antagonist or dopamine agonist to control biochemical…
- Trial name
- HOSCAR (NCT01278342)
- Testing
- Sandostatin LAR, pegvisomant, cabergoline
- Where
- 20 sites in France, Italy and 3 more
- Volunteers
- 70 people
- Sponsor
- Novartis Pharmaceuticals
Pituitary Macroadenoma
Radioactive Iodine Implants for Pan-invasive Pituitary Macroadenomas
This study is a single arm Phase II pilot trial. Patients enrolled on the trial will undergo implantation of high activity iodine-125 seeds into their pituitary adenoma.
- Trial name
- NCT01444209
- Testing
- Iodine Implants
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Texas Southwestern Medical Center
Growth Hormone Deficiency, Traumatic Brain Injury
Anterior Pituitary Hormone Replacement in Traumatic Brain Injury
Fifteen to twenty percent of adults who suffer a traumatic brain injury (TBI) that requires hospitalization and rehabilitation have been found to have growth hormone (GH) deficiency by GH stimulation testing.
- Trial name
- NCT00957671
- Testing
- Recombinant human growth hormone
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- The University of Texas Medical Branch, Galveston
Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma
18F-FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients With Newly-Diagnosed or Recurrent Gliomas
To evaluate 18F-FDOPA PET obtained from PET/CT or PET/MRI imaging in patients with newly diagnosed or recurrent gliomas.
- Conditions
- Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma, Adult Diffuse Astrocytoma
- Trial name
- NCT02175745
- Testing
- 18F-fluoro-dihydroxyphenylalanine, Positron emission tomography (PET), Computed tomography (CT)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Erik Mittra
Acromegaly
Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly
The objectives of the protocol is to determine the maximum tolerated dose and to investigate the pharmacokinetics of a single dose of lanreotide PRF in subjects with acromegaly.
- Trial name
- NCT02396953
- Testing
- Lanreotide PRF
- Where
- 36 sites in Belgium, Czechia and 10 more
- Volunteers
- 28 people
- Sponsor
- Ipsen
Brain Injuries, Growth Hormone Deficiency
Treatment Of Adult Growth Hormone Deficiency After Traumatic Brain Injury
To establish the effects of genotropin replacement on cognitive function in patients with severe growth hormone deficiency after traumatic brain injury.
- Trial name
- NCT00555009
- Testing
- Genotropin
- Where
- 9 sites in France, Italy and 4 more
- Volunteers
- 10 people
- Sponsor
- Pfizer
Cushing's Syndrome
Study to Evaluate CORT125134 in Participants With Cushing's Syndrome
Cushing's syndrome is a relatively rare disorder caused by prolonged exposure to high levels of the glucocorticoid hormone cortisol. Cushing's syndrome may result from elevated endogenous or exogenous sources of cortisol.
- Trial name
- NCT02804750
- Testing
- CORT125134
- Where
- 25 sites in United States, Hungary and 3 more
- Volunteers
- 35 people
- Sponsor
- Corcept Therapeutics
Acromegaly
Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly
The patients received either Pasireotide LAR or Octreotide LAR for one year of treatment. The objective of this study was to compare the proportion of patients with a reduction of mean GH level to <2.5 µg/L and the normalization…
- Trial name
- NCT00600886
- Testing
- Pasireotide, Octreotide
- Where
- 95 sites in United States, Argentina and 25 more
- Volunteers
- 358 people
- Sponsor
- Novartis Pharmaceuticals
Growth Hormone Deficiency, Septo-Optic Dysplasia
Endocrine Dysfunction and Growth Hormone Deficiency in Children With Optic Nerve Hypoplasia
Hypotheses: 1. The prevalence of endocrinopathies, and growth hormone (GH) deficiency in particular, among young children diagnosed with optic nerve hypoplasia (ONH) is higher than is commonly thought. 2.
- Conditions
- Growth Hormone Deficiency, Septo-Optic Dysplasia, Hypopituitarism
- Trial name
- NCT00140413
- Testing
- Nutropin AQ
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Children's Hospital Los Angeles
Asthma
Safety Study of the Effects of Inhaled Fluticasone Furoate/GW642444 on the Hypothalamic-Pituitary-Adrenal (HPA) Axis
The purpose of this study is to assess the effect of six weeks' treatment with two once-daily strengths of Fluticasone Furoate/GW642444 Inhalation Powder on the HPA axis system
- Trial name
- NCT01086410
- Testing
- Fluticasone Furoate/GW642444 Inhalation Powder, Prednisolone Oral Capsule
- Where
- 17 sites in United States, Germany and 1 more
- Volunteers
- 185 people
- Sponsor
- GlaxoSmithKline
Adult Growth Hormone Deficiency (AGHD)
Open-label Extension Study to Evaluate the Safety of Long-term Twice-monthly Administration of Somavaratan in Adult Growth Hormone Deficiency (AGHD)
Open-label extension study to evaluate the safety of long-term twice-monthly administration of somavaratan in adults with Growth Hormone Deficiency (GHD).
- Trial name
- NCT02719990
- Testing
- somavaratan
- Volunteers
- 36 people
- Sponsor
- Versartis Inc.